Risk stratification in acute coronary syndromes

Area of Science:

• Cardiology
• Interventional Cardiology
• Cardiovascular Medicine

Background:

• Effective risk stratification systems and antithrombotic agents are crucial for managing acute coronary syndrome (ACS) patients.
• Classical anti-ischemic drugs complement modern antithrombotic therapies in CCU settings.
• Knowledge of coronary anatomy is paramount for interventionalists to guide appropriate treatment strategies.

Purpose of the Study:

• To highlight the benefits of early angiography and invasive strategies in managing ACS patients.
• To discuss the role of percutaneous coronary intervention (PCI) and cardiac surgery in ACS treatment.
• To address the evolving treatment strategies for ST-elevation myocardial infarction (STEMI) versus non-ST-elevation myocardial infarction (NSTEMI).

Main Methods:

• Review of current noninvasive and invasive management approaches for ACS.
• Emphasis on the timing and benefits of coronary angiography.
• Discussion of percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG) indications.

Main Results:

• Early angiography benefits moderate to high-risk ACS patients; invasive approaches can reduce costs and length of stay even in low-risk patients when performed by expert teams.
• Cardiac surgery is a life-saving option for NSTEMI patients with cardiogenic shock, mechanical complications, or failed PCI.
• Complete myocardial revascularization via CABG may benefit stabilized patients with severe multivessel disease.

Conclusions:

• Modern ACS management relies on robust risk stratification, antithrombotic therapy, and timely invasive interventions.
• The distinction between STEMI and NSTEMI treatment strategies is diminishing with new evidence.
• Multidisciplinary 'heart team' evaluation is essential for complex revascularization decisions, including CABG.